Regulus Therapeutics (NASDAQ:RGLS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

Several other equities research analysts have also recently weighed in on RGLS. ValuEngine cut Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 8th. Wedbush restated a “hold” rating and set a $1.00 target price on shares of Regulus Therapeutics in a research note on Monday, December 16th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $1.31.

NASDAQ RGLS traded up $0.02 on Tuesday, hitting $1.25. 1,901 shares of the company’s stock were exchanged, compared to its average volume of 491,651. The stock has a 50-day moving average of $0.87 and a 200-day moving average of $0.80. Regulus Therapeutics has a 52 week low of $0.50 and a 52 week high of $1.74. The stock has a market cap of $25.74 million, a price-to-earnings ratio of -0.22 and a beta of 1.57.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. On average, equities research analysts anticipate that Regulus Therapeutics will post -1.11 EPS for the current year.

A hedge fund recently bought a new stake in Regulus Therapeutics stock. Samsara BioCapital LLC purchased a new stake in Regulus Therapeutics Inc (NASDAQ:RGLS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 904,407 shares of the biopharmaceutical company’s stock, valued at approximately $1,131,000. Regulus Therapeutics comprises approximately 0.7% of Samsara BioCapital LLC’s portfolio, making the stock its 17th largest holding. Samsara BioCapital LLC owned 4.36% of Regulus Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 36.84% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Featured Article: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.